1[1]Barbalias GA, Nikiforidis G, Liatsikos EN. α-Blockers for the treatment of chronic prostatitis in combination with antibiotics[J]. J Urol, 1998,159(3):883～887.
2[2]Nickel JC, Nyberg LM, Hennenfent M. Research guidelines for chronic prostatitis: consensus report from the first National Institutes of Health International Prostatitis Collaborative Network [J]. Urology,1999,54(2):229～233.
3[3]Nickel JC.Effective office management of chronic prostatitis [J].Urol Clin North Am, 1998,25(4):667～684.
4[4]Litwin MS, McNaughton Collins M, Fowler FJ Jr, et al. The national institutes of health chronic prostatitis symptom index: development and validation of a new outcome measure chronic prostatitis collaborative research network[J]. J Urol, 1999,162(2):369～ 375.
5[5]Theodorou C, Konidaris D, Moutzouris G, et al. The urodynamic profile of prostatodynia [J]. BJU Int, 1999,84(4):461～463.
6[6]Barbalias GA. Clinical and theraputical guidelines for chronic prostatitis [J]. Eur Urol,2000,37(1):116～117.
7[7]Neal DE Jr, Moon TD. Use of terazosin in prostatodynia and validation of a symptom score questionnaire [J]. Urology, 1994,43(4):460～465.
8[8]Price DT, Schwinn DA, Lomasney JW,et al. Identification, quantification, and localization of mRNA for three distinct alpha1 adrenergic receptor subtypes in human prostate [J]. J Urol, 1993,150(4):545～551.
